A Receptor-Based Bioadsorbent to Target Advanced Glycation End Products in Chronic Kidney Disease

Current therapeutic interventions in the glycation pathway: evidence from clinical studies

(2012) L. Engelen et al.   DIABETES OBESITY & METABOLISM

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study

(2011) J. W. Nin et al.   DIABETES CARE

Advanced glycation end-products and the kidney

(2010) Martin Busch et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy

(2010) Sally A. Penfold et al.   KIDNEY INTERNATIONAL

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

(2009) A. Bierhaus et al.   DIABETOLOGIA

Receptor for AGE (RAGE) and its ligands—cast into leading roles in diabetes and the inflammatory response

(2009) Shi Fang Yan et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Serum Carboxymethyl-Lysine, a Dominant Advanced Glycation End Product, Is Associated With Chronic Kidney Disease: The Baltimore Longitudinal Study of Aging

(2009) Richard D. Semba et al.   JOURNAL OF RENAL NUTRITION

Accumulation of Advanced Glycation End Products and Chronic Complications in ESRD Treated by Dialysis

(2008) Robbert Meerwaldt et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimers Disease

(2008) Masayoshi Takeuchi et al.   CURRENT PHARMACEUTICAL DESIGN